For instance, antibodies designed to bind high-affinity receptors, such as those on transport mechanisms like the transferrin receptor or therapeutic targets such as amyloid-beta in Alzheimer’s disease, may experience enhanced retention due to these interactions [32]. This evidence concerns the gene TFRC and early-onset autosomal dominant Alzheimer disease.